Reports indicate that changes are needed to close the gap for Indigenous health

To the Editor: The summation by Russell that “the inescapable reality is that current primary care interventions are not working” overlooks evidence of significant improvements in the Northern Territory. The latest “closing the gap” report indicates that the Indigenous mortality gap in the Northern Territory should close within a generation.

Mortality among NT Indigenous adults has declined by a third since 2000. We attribute this positive outcome primarily to effective use of primary health care funding, which has been progressively increased and equitably distributed, since 2001. This money has funded universally adopted e-health solutions and NT key performance indicators, which drive continuous quality improvement initiatives. These are backed by common clinical guidelines, with increasing adherence rates, that are used in all Aboriginal primary health care clinics.

The statement “ACCHOs [Aboriginal community controlled health organisations] have had little influence on the mainstream health system” neglects experience in the NT, where the ACCHO sector is a co-owner of the NT Medicare Local and remains a critical driver in the NT Aboriginal Health Forum (NTAHF). Now in its 15th year, the NTAHF has secured government support for community control as the preferred model for delivering Aboriginal primary health care. The ACCHO sector is also a leader in developing and using clinical guidelines, mental health services, e-health, and continuous quality improvement programs. National policy should support the expansion and enhancement of Aboriginal community controlled primary health care services.

Pasqualina M Coffey
Public Health Registrar
Alex Hope
Public Health Medical Officer
John D Boffa
Chief Medical Officer

In reply: The letter from Coffey and colleagues helps make my case that a major role for Aboriginal community controlled health organisations (ACCHOs) in providing health care to Indigenous communities makes a real difference in the effectiveness and efficiency of service delivery. However, we cannot be certain that the progress made in reducing Indigenous mortality rates in the Northern Territory is the result of better health care; it may reflect improvements in the social determinants of health, such as education, housing and community violence.

Hospital data highlight that success is still a long way off. The ratio of Indigenous to non-Indigenous aged-standardised hospital separations for the NT is 7.9, compared with 2.5 for all jurisdictions. There is a clear relationship between the number of primary care visits and hospitalisation for Indigenous residents of the Territory who live in remote communities. For patients with diabetes, ischaemic heart disease and renal disease, around 22 to 30 primary care visits a year are needed to reduce hospitalisations to a minimum. That is why an increased role for ACCHOs is one of the keys to closing the gap.

Lesley M Russell
Visiting Fellow
Australian Primary Health Care Research Institute, Australian National University, Canberra, ACT.

Competing interests: No relevant disclosures.

doi: 10.5694/mja14.00057

1 Public Health Unit, Aboriginal Medical Services Alliance Northern Territory, Darwin, NT.
2 Public Health Division, Central Australian Aboriginal Congress, Alice Springs, NT.
alex.hope@amsant.org.au

The latest ‘closing the gap’ report indicates that the Indigenous mortality gap in the NT should close within a generation.

Coffey et al

The latest ‘closing the gap’ report indicates that the Indigenous mortality gap in the NT should close within a generation.

Russell

Engaging Aboriginal and Torres Strait Islander men in primary care settings

To the Editor: It is well recognised that Aboriginal and Torres Strait Islander men are one of the most disadvantaged population groups in Australia in terms of physical wellbeing. Annual Medicare Benefits Schedule health assessment items are essential tools to help Aboriginal and Torres Strait Islander men (and women and children) receive primary health care matched to their needs, as well as opportunities for preventive health care and education.

A growing body of evidence suggests that erectile dysfunction (ED) coexists with, or is a clinical marker for, common life-threatening conditions, such as coronary heart disease and type 2 diabetes, due to shared underlying neurovascular mechanisms. Indeed, the relative risk and severity of coronary artery disease appears to be higher for young men reporting ED. Despite this, discussion with Aboriginal and Torres Strait Islander men about sexual health is often lacking. In such population groups at risk of chronic disease, the opportunity to assess erectile function may present a window of opportunity to identify and better manage life-threatening disease.

To engage these men in sexual health discussions, a greater focus on culturally appropriate health services is needed. Cultural competency training is essential to overcome the barriers affecting how Aboriginal
Factors influencing health service access and help-seeking behaviour for Aboriginal and Torres Strait Islander men

Societal
- Illness-related stigma
- Sex-specific differences in health

Cultural
- Traditional gender-related law, masculinity and gender roles
- Language barriers
- Beliefs around causation

Logistical
- Lack of transport
- Conflict of appointment times with other family and community priorities (e.g., ceremonies)

Health system
- Limited access to specialist services and/or treatment
- Complicated referral process
- Too few (male) health professionals, leading to patients seeing many different doctors
- Medical terminology and jargon

Financial
- Difficulties in meeting health service costs

Individual
- Knowledge or perception of the nature of the illness
- Previous illness experience
- Low prioritisation of preventive health care
- Lack of understanding and embarrassment
- Low self-esteem and confidence

Examples of culturally appropriate strategies for engaging with Aboriginal and Torres Strait Islander men about sexual health issues

- Provide a safe, private and comfortable environment that supports open and free dialogue
- Men may not open up in the first consultation — take time to build trust and respect
- Encourage men to have annual health assessments and incorporate sexual health questioning into these
- Make the clinic conducive to talking about sensitive issues; for example, a model of the male pelvis in the consulting room might help initiate discussion
- If only female health care providers are available, approach gender-specific issues in a sensitive way and use male Aboriginal health workers for advice or, if not urgent, refer to a male general practitioner

Carol A Holden Chief Executive Officer
1 Anunipima Cape York Health Council, Cairns, QLD.
2 National Aboriginal Community Controlled Health Organisation, Canberra, ACT.
3 Centre for Health and Wellbeing, Australian Institute of Aboriginal and Torres Strait Islander Studies, Canberra, ACT.
4 Andrology Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC.
carol.holden@monash.edu

Acknowledgements: We acknowledge and thank the members of the Andrology Australia Aboriginal and Torres Strait Islander Male Health Reference Group for their ongoing advice and contribution to our work in this area. The Andrology Australia program is supported by the Australian Government Department of Health. The department played no role in the writing of this letter.

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00160

Re-infection and relapse are common, and failure to effectively manage core transmitters results in a cycle of infection that demoralises communities.

To the Editor: Scabies continues to cause significant morbidity among residents of Indigenous communities. In the Northern Territory, scabies underlies most cases of Streptococcus pyogenes pharyngitis, a major cause of poststreptococcal glomerulonephritis and rheumatic fever. The increased risk of scabies resulting from infection with the human T-lymphotropic virus type 1 (HTLV-I) has received little attention. This human retrovirus is endemic to much of Western Australia, South Australia and the NT. In a recent study, 33% of nearly 1600 Indigenous adults tested at Alice Springs Hospital (ASH) were infected.

We report the case of a 36-year-old HTLV-I-infected Indigenous man from an Alice Springs town camp who was admitted to ASH with severe crusted scabies. Since early childhood, he had been hospitalised six times with recurrent scabies and had also been admitted with intestinal strongyloidiasis and chronic supplicative lung disease. On examination, he had confluent areas of hyperkeratosis with profuse skin shedding, deep skin cracks, bleeding and ooze involving the lower half of his body (Box). Skin scrapings revealed numerous scabies mites. Full blood examination showed an eosinophilia (2.6 × 10^9/L; reference interval [RI], 0–0.4 × 10^9/L) and markedly elevated IgE levels (177,000 kU/L; RI, < 110 kU/L). HTLV-I infection was confirmed by western blot at the National Serology Reference Laboratory. The HTLV-I proviral load was high, at 1.29 × 10^10 peripheral blood mononuclear cells. High HTLV-I proviral loads have been associated with strongyloidiasis and HTLV-I-driven inflammatory diseases. Serological testing for Strongyloides was negative and no other cause of immunodeficiency was found. Treatment of household contacts and cleaning of accommodation proved...
Partial foot amputations may not always be worth the risk of complications

To the Editor: In their recent article, Dillon and colleagues cite reports that the incidence of partial foot amputations is rising and that the functional outcome of these amputations is poor. They express difficulty in understanding “why the high risk of complications and secondary amputations associated with partial foot amputation do not weigh more heavily in decisions about amputation surgery”. Finally, they propose that more transplantable than partial foot amputations should be considered to minimise the risk of complications and further amputation.

The authors’ argument is misleading as they combine two very different entities, toe amputation and major foot amputation, as the single entity of “partial foot amputation”. As their own work has shown, two amputations make up 90% of all “partial foot amputations” and it is mainly toe amputations that are becoming more common. The evidence they cite about complications and poor outcomes in “partial foot amputations” is based exclusively on (less commonly performed) transmetatarsal and midfoot amputations, and not on toe amputations. While the early amputations are slightly more common, they combine two very different entities, toe amputation and major foot amputation, and the functional outcome is much worse than that of toe amputation alone.

Norman et al
morbidity of toe (± metatarsal head) amputation is not insignificant, the late functional outcomes are likely to be more favourable than transmetatarsal or midtarsal amputation.

Our interpretation of the available evidence is that the rising incidence of “partial foot amputations” is driven by more toe amputations in the increasing number of people with type 2 diabetes. This preserves acceptable function and may be contributing to the decline in major amputations. We acknowledge that further research is needed to clarify the relationship between these diverging trends.

Paul E Norman Professor of Vascular Surgery, School of Surgery
Deborah E Schoen Podiatrist, Western Australian Centre for Rural Health
Lee Nekkoff Research Associate, Cardiovascular Research Group, School of Population Health
University of Western Australia, Perth, WA.
lee.nekko@uwa.edu.au

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00506


To the Editor: Dillon and colleagues present a challenging perspective on the evidence comparing partial foot amputation (PFA) and below-knee amputation (BKA) outcomes.1-2 Australia’s diabetes-related major amputation rates have only recently reduced to international levels3 and we fear that any oversimplistic perspectives may be detrimental to these improved rates and, importantly, to our patients. Thus, we believe these articles1,2 should be read cognisant of some important points.

First, the authors correctly identify that 75% of Australia’s amputations are PFAs (toe, ray or transmetatarsal amputations [TMA]),4 yet base their PFA arguments nearly entirely on TMA literature.1,3 TMA amputations are complex procedures and make up just 5%-10% of PFAs.4 Thus, we believe the article should be primarily read as a comparison between TMA and BKA outcomes.

Second, the authors correctly report higher ipsilateral reamputation risks for TMAs compared with BKAs;1,2 however, they omit lower contralateral amputation risks5 and somewhat dismiss well reported lower mortality risks.1,5

Last, the authors conclude “very similar functional outcomes” from data comparing methodologically different TMA studies with BKA studies or data within heterogeneous and underpowered studies.1,2 These definitive interpretations may be misleading, especially given the statistically significant functional benefits of TMAs compared with BKAs, as reported in the higher impact studies the authors cite.2,6

We thank Dillon et al for highlighting such a large, yet silent, burden of disease and hope this letter will provide more balance to this crucial life-changing decision facing 8000 Australians and their clinicians this year.4

Peter A Lazzarini Senior Research Fellow1,2
Matthew Malone Head of Department2
Paul R Wright Head of Department4

1 School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD.
2 Allied Health Research Collaborative, Metro North Hospital and Health Service, Brisbane, QLD.
3 High Risk Foot Service, Liverpool Hospital, Sydney, NSW.
4 Diabetic Foot Unit, Royal Melbourne Hospital, Melbourne, VIC.
Peter.Lazzarini@health.qld.gov.au

Competing interests: No relevant disclosures.
doi: 10.5694/mja14.00476


In reply: We appreciate the opportunity to reply to two letters submitted in response to our article.1 Both letters agree that our perspective piece was mainly based on evidence about the outcomes for people with transmetatarsal amputation, noting that most people undergo amputation of the toe(s) or toes and metatarsals. As highlighted in our supporting work,2 there are comparatively few investigations focusing on outcomes for people with digital, ray, tarsometatarsal and transtarsal amputation. Despite this, we stand by our interpretation that the rates of complications and reamputation seem very similar across levels of partial foot amputation.1,2 To illustrate, a study that stratified large numbers of people by level of partial foot amputation found that the rates of ipsilateral reamputation were not statistically different in groups with either toe, ray or mid-foot (ie, transmetatarsal, Lisfranc and Chopart) amputation.3 Given these data, we argue that our synthesis of published outcomes on the rates of reamputation and other complications for people with different levels of partial foot amputation was reasonable. Our article should not be considered a comparison between the outcomes of transmetatarsal and transtibial amputation.

We do not believe that current data show that toe amputations are becoming more common in Australia. The age-standardised incidence of toe amputation remained stable between 2000 and 2010, while the incidence of partial foot amputation at the toe and metatarsal level and transmetatarsal level increased.4

We are not advocating that more transtibial amputations should be considered to minimise the risk of complications and further amputations. Rather, clinicians should consider the emerging evidence when communicating the perceived benefits to patients; particularly given that this evidence challenges long-held beliefs.2 We are grateful for the opportunity to promote discussion and highlight awareness of the need for further research into outcomes.
for people facing difficult decisions about limb loss.

**Michael P Dillon** Senior Lecturer, National Centre for Prosthetics and Orthotics

**Stefania Fatone** Associate Professor

**Meg E Morris** Professor, School of Allied Health

1 La Trobe University, Melbourne, VIC.

2 Northwestern University Prosthetics-Orthotics Center, Northwestern University, Chicago, Ill, USA.

Michael.Dillon@latrobe.edu.au

Competing interests: No relevant disclosures.

doi: 10.5694/mja14.00629

---

**Stefania Fatone**

**Michael P Dillon**

Deliberations about limb loss.

Off-label prescribing is a complex paradigm, with important clinical, safety, ethical, legal and financial dimensions. The articles by Seale,1 Hickie,2 and Harris and Naylor3 highlight some associated controversies and the need for a rigorous approach.

The Council of Australian Therapeutic Advisory Groups (CATAG) has recently developed national guiding principles that provide a structured framework to support judicious, appropriate, safe, effective and cost-effective off-label use of medicines.4 This framework will facilitate a more rigorous and consistent approach to decision making by health professionals, consumers, and drug and therapeutics committees in their evaluation and use of medicines that are prescribed off label. CATAG's guidance provides an important expansion and update on previous Australian recommendations.5

There are seven overarching guiding principles, including a core principle of systematic evaluation of the evidence base and risk–benefit ratio for proposed off-label uses. Comprehensive advice for involving patients and carers in shared decision making and systematic outcomes evaluation is also provided. Applying these principles in routine practice will help address the clinical, safety and ethical concerns that have recently been highlighted. CATAG anticipates undertaking future work to support wider implementation of the guiding principles.

**Madlen Gazarian** Specialist Advisor and Co-Chair, Off-label Expert Advisory Group,1 and Honorary Associate Professor

**Steve Morris** OAM1

1 Council of Australian Therapeutic Advisory Groups, Sydney, NSW.

2 School of Medical Sciences, University of New South Wales, Sydney, NSW.

M.Gazarian@unsw.edu.au

**Acknowledgements**: CATAG is supported by funding from NPS MedicineWise, an independent not-for-profit public company funded by the Australian Government Department of Health. This funding is managed through a services agreement between NPS MedicineWise and the New South Wales Therapeutic Advisory Group, an independent, not-for-profit member-based organisation supported by the NSW Ministry of Health.

**Competing interests**: No relevant disclosures.

doi: 10.5694/mja14.00577

---


---

**CATAG [provides] a structured framework to support judicious, appropriate, safe, effective and cost-effective off-label use of medicines**

**Madlen Gazarian** et al